NOVATO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the successful completion of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting its Phase 3 study plans for GTX-102, an antisense ...
The FDA will hold an end-of-phase 2 meeting to discuss botensilimab plus balstilimab for the treatment of patients with relapsed/refractory metastatic colorectal cancer. FDA The FDA will hold a Type B end-of-phase 2 meeting with Agenus to discuss studies investigating the combin...
"We are pleased to announce that, earlier this quarter, we had a very productive End-of-Phase 2 meeting with the FDA," saidRick Hawkins, Chairman and CEO ofLumos Pharma. "In this review, the FDA recognized LUM-201's unique mechanism as a growth hormone secretagogue and a...
The article reports on the approval of the Food and Drug Administration (FDA) for an End of Phase II meeting with TNI BioTech Inc. to discuss its clinical development program and chemistry ...
IMUNON, Inc. recently announced the outcome of its recent End-of-Phase 2 in-person meeting with the US FDA, supporting the advancement of its
HIGH POINT, N.C.--(BUSINESS WIRE)--TransTech Pharma Inc. announced today that it has successfully completed an End of Phase 2 meeting for TTP488 wi
Oramed PharmaceuticalsJosh HexterOffice: +972-2-566-0001 ext. 2 US: 1-718-831-2512 ext. 2 Email:josh@oramed.com View original content:http://www.prnewswire.com/news-releases/oramed-announces-end-of-phase-2-meeting-with-fda-to-initiate-phase-3-program-300485879.html ...
Aquestive Therapeutics, Inc. today announced the completion of its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (“FDA”) for AQST-109 (epinephrine sublingual film) for the treatment of severe allergic reactions includ...
Bionomics Limited announced that the last patient last visit has been completed in its Phase 2 ATTUNE study in PTSD, and disclosed timing of the End of Phase 2 meeting to review advancing BNC210 into...
“The Phase 2 end of study data that I presented at The Retina Society Annual Meeting showed 80% tumor control rate, 90% vision preservation, and a highly favorable safety profile in early-stage CM. Bel-sar has t...